On the stock market since 2012, it operates in the world of health and science. It has 778 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 15% below its peak. The market has trimmed its expectations for the company.
The company sells $719.0M a year; the problem isn’t sales — it’s costs running above that number.
There is $308.7M in the vault; even if every debt were paid off, $267.7M would remain.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
A loss of $38.6M against $719.0M in annual sales.
The growth engine is running at low revs right now. Report-card grade: 13/100.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
On our five-subject report card, SUPN sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: SUPN has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.